LOC728756 Inhibitors

Wortmannin and Triciribine, which could attenuate the PI3K/Akt signaling pathway; U0126, which inhibits the MEK/ERK pathway; and PP2, which affects Src family kinases. By inhibiting these kinases, the compounds can modify phosphorylation patterns that may be essential for LOC728756's function or interaction with other proteins. Rapamycin, with its mTOR inhibitory effects, could suppress cellular growth and proliferation signals potentially connected to LOC728756. SB431542 and BML-275 represent molecules that target growth factor signaling, with SB431542 affecting the TGF-beta pathway and BML-275 affecting BMP signaling, both of which could intersect with LOC728756's activity.

Compounds like Bortezomib alter protein turnover by inhibiting the proteasome, which could impact the stability or degradation rate of LOC728756. On the other hand, KN-93, Thapsigargin, and Y-27632 alter intracellular calcium levels and cytoskeleton dynamics, which could influence LOC728756 if it is regulated by calcium signaling or involved in cell motility. PD173074 provides a targeted approach to inhibit FGFR signaling, which could be a part of the regulatory network for LOC728756.